Skip to main content
Log in
Sciensano
Support
Belgian Genetic Tests database
Toggle navigation
Main navigation
Home
Genetic tests
Analytes
Diseases
Labs
Guide
Contact
Genetic tests
20
50
100
Search
Full name
Analytes
Gene panels
Disease
Laboratory
Venous malformation (3 genes)
TEK
,
GLMN
Venous malformation (3 genes) - UCL
,
Vascular malformations (germline) (38 genes) - UCL
Blue rubber bleb nevus
,
Mucocutaneous venous malformations
,
Glomuvenous malformation
,
Bannayan-Riley-Ruvalcaba syndrome
,
Cowden syndrome
,
Juvenile polyposis of infancy
,
Proteus syndrome
,
Proteus-like syndrome
,
Segmental outgrowth-lipomatosis-arteriovenous malformation-epidermal nevus syndrome
Centre de Génétique Médicale UCL
Cowden disease / PTEN hamartoma tumor syndrome
PTEN
Cowden syndrome
,
Bannayan-Riley-Ruvalcaba syndrome
,
Proteus syndrome
Centrum Medische Genetica - UZ Gent
Cowden disease (PTEN gene)
PTEN
Cowden syndrome
Centre de Génétique Humaine - CHU Sart-Tilman
Hemophilia B
F9
Hemophilia B
,
Severe hemophilia B
,
Moderate hemophilia B
,
Mild hemophilia B
,
Bleeding disorder in hemophilia B carriers
Centre de Génétique Médicale UCL
Hemophilia B
F9
Hemophilia B
,
Severe hemophilia B
,
Moderate hemophilia B
,
Mild hemophilia B
,
Bleeding disorder in hemophilia B carriers
Centrum Menselijke Erfelijkheid - KUL
CYP2C9*2,*3 genotyping - drug metabolism - Pharmacogenetics
CYP2C9
Vitamin K antagonists toxicity or dose selection
,
Oral antidiabetic drugs toxicity or dose selection
Centre de Génétique Médicale UCL
Vitamin K antagonists toxicity or dose selection - VKORC1 genotyping (-1639G>A + 1173C>T) - Pharmacogenetics
VKORC1
Vitamin K antagonists toxicity or dose selection
,
Prediction of toxicity or dose selection of vitamin K antagonists
Centre de Génétique Médicale UCL
Hyperoxaluria
AGXT
,
GRHPR
,
HOGA1
Primary hyperoxaluria type 1
,
Primary hyperoxaluria type 2
,
Primary hyperoxaluria type 3
Centre de Génétique-Institut de Pathologie et de Génétique (IPG)
Did not find what you were looking for? Contact us through the support center.
Read more